Researchers from Scynexis Inc. have recently presented details on the preclinical characterization of SCY-247, a second-generation triterpenoid with glucan synthase inhibitor activity and intended to be used for the treatment of invasive mucormycosis.
At the IDWeek 2023 infectious disease conference held last week in Boston, fungal infections got the audience’s attention during the session titled, “The antifungal evolution: novel strategies for a changing world.” With the emergence of some resistant pathogens such Candida auris and the growing disease burden in the population at risk for life-threatening fungal infections, these pathogens are more than ever standing out within the infectious diseases arena.
Fearing cross contamination might have occurred during manufacturing, Scynexis Inc. is recalling Brexafemme (ibrexafungerp tablets) from the market and putting a temporary hold on the drug’s clinical trials until it knows more details.
Researchers from University of Toronto and affiliated organizations have presented the discovery and preclinical evaluation of novel inhibitors of fungal fatty acid biosynthesis as potential antifungal agents. High-throughput screening of a library of natural products against representative isolates of four major human pathogenic yeast species (Candida albicans, C. glabrata, C. auris, C. neoformans) resulted in the discovery of the triazenyl indole NPD-6433.
What could be the first newly approved antifungal in nearly 20 years based on a novel mechanism hit a bump as F2G Ltd. has received a complete response letter from the U.S. FDA.
The Research Foundation of State University of New York has identified compounds targeting the synthesis of fungal sphingolipids, particularly ceramide glucosyltransferase (glucosylceramide) inhibitors, reported to be useful for the treatment of fungal infections.
